Clinical trialNCT01265511CompletedPhase 2Interventional

Study of SCY-635, Pegasys and Copegus in Hepatitis C

SponsorScynexis, Inc.Enrollment10Hepatitis C Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The Week 24 visit will be the last on-study visit. After the Week 24 visit, all subjects with undetectable HCV RNA will be given the option to continue treatment with standard of care for an additional 24 weeks (out to Week 48) under the care of their Principal Investigator.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Andrew J Muir, MD
Duke Clinical Research Institute
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Keyur Patel, MD
Duke Clinical Ressearch Institute
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Fundacion de Investigation de Diego
San Juan, Puerto Rico

United States

Quest Clinical Research
San Francisco, California, United States
Duke University Medical Center
Durham, North Carolina, United States
Alamo Medical Research
San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CopegusPegasysPlaceboSCY-635

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2010
Primary completion: 31 Oct 2011
Completion: 31 Oct 2011
Last update posted: 18 Aug 2017
Registered enrollment: 10
Registry id: NCT01265511

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.